BIOCRYST PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $874.8 | $450.7 | $331.4 | $270.8 | $157.2 |
| Operating income | $341.0 | -$2.5 | -$103.7 | -$148.4 | -$177.7 |
| Net income | $263.9 | -$88.9 | -$226.5 | -$247.1 | -$184.1 |
| Cash Flow Statement | |||||
| Free cash flow | $344.9 | -$53.1 | -$97.3 | -$163.2 | -$144.5 |
Shares outstanding 255.5M · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of September 21, 2026.